Keyword: Valeant Pharmaceuticals
Bausch has changed its name and more to move on from the Valeant history. Now, it's settling an investor class action lawsuit for $1.2 billion.
While many of the decade's M&A deals worked out for the buyers, others didn't deliver on their promises. Here, we feature 15 of those deals, including Bayer's Monsanto buy, Teva's purchase of Allergan's generics, AbbVie's Synageva pickup and many others.
AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.
Two Republican lawmakers advised drugmakers to not participate in a drug pricing probe in a House committee.
Bausch Health is working to pay down debt and focusing on "organic growth," but one analyst says the company hasn't changed much from the old Valeant.
Bausch hopes it can turn around Synergy's struggling constipation drug Trulance to complement its own Xifaxan.
Though Cosmo's Aemcolo is now only approved in travelers' diarrhea, it could soon tap into Xifaxan's much larger IBS-D market, one analyst predicts.
Attorneys for both defendants, Valeant's former executive Gary Tanner and ex-Philidor CEO Andrew Davenport, say they'll appeal the convictions.
Perrigo CEO Uwe Roehrhoff is stepping down effective immediately, the company announced, to be replaced by former tobacco executive Murray Kessler.